CORDIS
EU research results

CORDIS

English EN

Nano-confined photonic system for detection of breast cancer spread to the lymph nodes

Objective

The Vision of HypoSens is to develop a widely accepted,non-invasive and crucial prognostic tool for breast cancer progression in early stages to help clinicians and specially oncologists to decide about prompt therapy approaches to patients and improve quality of life and expectancy. Our breakthrough research will focus on the development, pre-clinical and clinical validation, and industrial demonstration of a unique all optical cancer prognostic system that will determine presence of cancer cells in the breast lymph nodes and characterize them, which correlates with presence of metastasis and bad prognosis. HypoSens prognostic system will consist of a non-invasive Near-infrared imaging device able to register signals through scattering media enabled by the implementation of wavefront shaping,that will process data collected by injected tumour-targeted body antibody functionalised nano-particles containing porphyrin sensors that will determine local oxygen concentration and local temperature distribution in the cancer cells.The HypoSens imaging system is strategically designed to offer a non-invasive alternative to the Sentinel Lymph Node Biopsy,the current surgical procedure for breast cancer staging. With an approximate cost of 60,000€ per device unit and additional 5,000€ per patient, the device is an affordable, accurate, easy to use prognostic solution for clinicians towards more accurate and fast diagnostics and personalised treatment options.The initial target of the project is metastatic breast cancer, with potential later involvement in other cancer markets, e.g. vulval, renal, colorectal, gastric etc (via the use of different tumor-targeting moiety).With an estimated 1.7 million new cases each year, breast cancer is the most common cancer among women worldwide.Its low cost will enable a wide and fast take-up by clinicians and hospitals leading to an important reduction of the economic and societal burden related to the diagnosis and treatment of cancer.

Coordinator

ACONDICIONAMIENTO TARRASENSE ASSOCIACION

Address

Carrer De La Innovacio 2
08225 Terrassa

Spain

Activity type

Research Organisations

EU Contribution

€ 672 083,75

Participants (10)

Sort alphabetically

Sort by EU Contribution

Expand all

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV

Germany

EU Contribution

€ 490 981,25

FUNDACION RIOJA SALUD-FRS

Spain

EU Contribution

€ 407 677,50

SOFIA UNIVERSITY ST KLIMENT OHRIDSKI

Bulgaria

EU Contribution

€ 403 162,50

TECNOLOGIAS AVANZADAS INSPIRALIA SL

Spain

EU Contribution

€ 83 551

TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY

Israel

EU Contribution

€ 539 041,25

BCB Informatica y Control S.L.

Spain

EU Contribution

€ 372 500

OBELIS SA

Belgium

EU Contribution

€ 319 200

KNOWLEDGE INNOVATION MARKET S.L.

Spain

EU Contribution

€ 240 250

UFO

Albania

EU Contribution

€ 193 750

FUNDACION PARA EL DESARROLLO Y LA INNOVACION TECNOLOGICA

Spain

EU Contribution

€ 276 449

Project information

Grant agreement ID: 732794

Status

Ongoing project

  • Start date

    1 November 2016

  • End date

    31 October 2019

Funded under:

H2020-EU.2.1.1.

  • Overall budget:

    € 3 998 646,25

  • EU contribution

    € 3 998 646,25

Coordinated by:

ACONDICIONAMIENTO TARRASENSE ASSOCIACION

Spain